These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20664958)

  • 21. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
    Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model.
    Kamada Y; Matsumoto H; Tamura S; Fukushima J; Kiso S; Fukui K; Igura T; Maeda N; Kihara S; Funahashi T; Matsuzawa Y; Shimomura I; Hayashi N
    J Hepatol; 2007 Oct; 47(4):556-64. PubMed ID: 17459514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nitric oxide plays a crucial role in the development/progression of nonalcoholic steatohepatitis in the choline-deficient, l-amino acid-defined diet-fed rat model.
    Fujita K; Nozaki Y; Yoneda M; Wada K; Takahashi H; Kirikoshi H; Inamori M; Saito S; Iwasaki T; Terauchi Y; Maeyama S; Nakajima A
    Alcohol Clin Exp Res; 2010 Feb; 34 Suppl 1():S18-24. PubMed ID: 18986378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis.
    Ibañez P; Solis N; Pizarro M; Aguayo G; Duarte I; Miquel JF; Accatino L; Arrese M
    J Gastroenterol Hepatol; 2007 Jun; 22(6):846-51. PubMed ID: 17565640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro.
    Yu J; Zhang S; Chu ES; Go MY; Lau RH; Zhao J; Wu CW; Tong L; Zhao J; Poon TC; Sung JJ
    Int J Biochem Cell Biol; 2010 Jun; 42(6):948-57. PubMed ID: 20156580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis.
    Kitade M; Yoshiji H; Kojima H; Ikenaka Y; Noguchi R; Kaji K; Yoshii J; Yanase K; Namisaki T; Yamazaki M; Tsujimoto T; Moriya K; Kawaratani H; Akahane T; Fukui H
    Mol Med Rep; 2008; 1(4):543-8. PubMed ID: 21479447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic steatohepatitis.
    Brunt EM
    Semin Liver Dis; 2004 Feb; 24(1):3-20. PubMed ID: 15085483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
    Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
    Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II type 1 receptor antagonist improves the prognosis in rats displaying liver cirrhosis induced by a choline-deficient diet.
    Iwata K; Sohda T; Irie M; Takeyama Y; Anan A; Shakado S; Sakisaka S
    J Gastrointestin Liver Dis; 2008 Mar; 17(1):21-5. PubMed ID: 18392239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.
    Tamaki Y; Nakade Y; Yamauchi T; Makino Y; Yokohama S; Okada M; Aso K; Kanamori H; Ohashi T; Sato K; Nakao H; Haneda M; Yoneda M
    J Gastroenterol; 2013 Apr; 48(4):491-503. PubMed ID: 22886508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice.
    Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Yoshii J; Yanase K; Namisaki T; Yamazaki M; Tsujimoto T; Kawaratani H; Fukui H
    Hepatol Res; 2010 May; 40(5):540-9. PubMed ID: 20412330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of aldosterone and spironolactone on the proliferation and collagen synthesis of hepatic stellate cells in rats].
    Yao JF; Yao XX; Fang HM; Cui DL; Bai WY
    Zhonghua Yi Xue Za Zhi; 2003 Oct; 83(20):1823-5. PubMed ID: 14642092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Yoshii J; Ikenaka Y; Noguchi R; Yanase K; Tsujinoue H; Imazu H; Fukui H
    Int J Oncol; 2002 Jun; 20(6):1227-31. PubMed ID: 12012003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Connexin 32 and luteolin play protective roles in non-alcoholic steatohepatitis development and its related hepatocarcinogenesis in rats.
    Sagawa H; Naiki-Ito A; Kato H; Naiki T; Yamashita Y; Suzuki S; Sato S; Shiomi K; Kato A; Kuno T; Matsuo Y; Kimura M; Takeyama H; Takahashi S
    Carcinogenesis; 2015 Dec; 36(12):1539-49. PubMed ID: 26494227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mechanism of hepatocyte regeneration inhibition in rats with liver fibrosis induced by lipogenic methionine-choline- deficient diet].
    Mu YP; Xi XH; Chen XR
    Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(48):3430-6. PubMed ID: 20223120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis.
    Rombouts K; Marra F
    Dig Dis; 2010; 28(1):229-35. PubMed ID: 20460917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
    Namisaki T; Noguchi R; Moriya K; Kitade M; Aihara Y; Douhara A; Nishimura N; Takeda K; Okura Y; Kawaratani H; Takaya H; Seki K; Yoshiji H
    J Gastroenterol; 2016 Feb; 51(2):162-72. PubMed ID: 26190501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Miele L; Forgione A; Gasbarrini G; Grieco A
    Transl Res; 2007 Mar; 149(3):114-25. PubMed ID: 17320797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.